Citations

Clear

158 citation(s) found for "Hartman, A-R".

Spatial Resolution and Radiation Dose of a 64-MDCT Scanner Compared with Published CT Urography Protocols
Vrtiska, Terri J., Hartman, Robert P. , Kofler, James M., Bruesewitz, Michael R. , King, Bernard F., McCollough, Cynthia H.

Mayo Clinic

American Journal of Roentgenology | March 20, 2009 | Volume: 192 | Issue: 4 | Pages: 941-948

10.2214/ajr.07.2679 | PMID 19304698 Get It

Use of IV Epinephrine for Treatment of Patients with Contrast Reactions: Lessons Learned from a 5-Year Experience
Collins, Mark S., Hunt, Christopher H. , Hartman, Robert P. , Hunt, Christopher H

Mayo Clinic

American Journal of Roentgenology | January 20, 2009 | Volume: 192 | Issue: 2 | Pages: 455-461

10.2214/ajr.08.1542 | PMID 19155410 Get It

Effect of Dehydroepiandrosterone Replacement on Lipoprotein Profile in Hypoadrenal Women
Srinivasan, Manivannan , Irving, Brian A. , Klaus, Katherine A. , Hartman, Stacy, McConnell, Joseph P., Dhatariya, Ketan , Nair, K. Sreekumaran

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 10, 2008 | Volume: 94 | Issue: 3 | Pages: 761-764

10.1210/jc.2008-1774 | PMID 19066301 Get It

Abstract Context: Levels of dehydroepiandrosterone (DHEA) and its sulfate form (DHEAS) are inversely associated with cardiovascular mortality in men but not women. Very little evidence is available on the impact of DHEA administration on lipoprotein profile in women. DHEAS levels are very low/undetectable in hypoadrenal women. Objective: The objective of the study was to determine the impact of DHEA replacement on lipoprotein profile in hypoadrenal women. Design and Setting: A double-blind, randomized, placebo-controlled, cross-over design study was conducted at the Mayo Clinic. Participants: Thirty-three hypoadrenal Caucasian women (mean ± sd; age 50.3 ± 15.2 yr, body mass index 26.6 ± 4.4 kg/m2) took part in the study. Intervention: Study participants were assigned to receive either a placebo or 50 mg/d of DHEA for 3 months each. Lipid levels and lipoprotein profile were analyzed using the Lipo Science Lipoprotein nuclear magnetic resonance system. Main Outcome Measures: Changes in various lipoprotein sizes and levels were measured. Results: The DHEA period had higher plasma DHEAS levels than during placebo (<0.3 ± 0.0 vs. 3.5 ± 1.3 nmol/liter, P < 0.001). DHEA replacement significantly reduced total cholesterol (20.0 vs. −22, P = 0.02) and high-density lipoprotein (HDL) levels (2.0 vs. −6.0, P = 0.006) and tends to reduce triglyceride and total low-density lipoprotein levels. Although, DHEA replacement had no effect on low-density lipoprotein particle size, it significantly reduced larger HDL particles and to modest extent small HDL particles. Conclusions: Our study findings showed that oral DHEA administration in hypoadrenal women results in an unfavorable lipoprotein profile. The results warrant long-term studies to determine the impact of DHEA replacement on cardiovascular risk.
Dual-Energy CT Iodine-Subtraction Virtual Unenhanced Technique to Detect Urinary Stones in an Iodine-Filled Collecting System: A Phantom Study
Takahashi, Naoki , Hartman, Robert P. , Vrtiska, Terri J., Primak, Andrew N. , Dzyubak, O. P. , Mandrekar, Jayawant N. , Kawashima, Akira , Fletcher, Joel G. , McCollough, Cynthia H. , Takahashi, Naoki

Mayo Clinic

American Journal of Roentgenology | April 22, 2008 | Volume: 190 | Issue: 5 | Pages: 1169-1173

10.2214/ajr.07.3154 | PMID 18430827 Get It

Aspirin Responsiveness in Healthy Volunteers Measured with Multiple Assay Platforms
Karon, Brad S. , Wockenfus, Amy M., Scott, Renee, Hartman, Stacy, McConnell, Joseph P., Santrach, Paula J., Jaffe, Allan S. , Jaffe, Allan S.

Mayo Clinic

Clinical Chemistry | April 17, 2008 | Volume: 54 | Issue: 6 | Pages: 1060-1065

10.1373/clinchem.2007.101014 | PMID 18420732 Get It

Abstract Background: We evaluated the sensitivity, precision, and concordance of 4 assays designed to detect aspirin responsiveness or resistance. Methods: Twenty-nine healthy laboratory volunteers took 80 mg aspirin for 7 days, and a subset of volunteers took 325 mg aspirin for an additional 7 days. We measured platelet function by light transmission aggregometry with arachidonic acid, PFA-100, and VerifyNow. PFA-100 and VerifyNow assays were performed in duplicate to assess method imprecision. Some volunteers had samples taken within 2–4 h of the final dose of aspirin and again within 20–24 h of the final dose. We measured urinary 11-dehydro-thromboxane B2 at baseline and after 80 or 325 mg aspirin. Results: No volunteers were nonresponsive to aspirin therapy as measured by the PFA-100. One of 29 participants demonstrated lack of response to aspirin as measured by VerifyNow and urinary 11-dehydro-thromboxane B2; 2 of 29 demonstrated lack of response as measured by light transmission aggregometry. Imprecision was <10% for the PFA-100 and VerifyNow. Concordance was high (>90%) between all assays. Neither aspirin dose (80 vs 325 mg) nor timing between final dose of aspirin and blood draw (2–4 vs 20–24 h) affected any of the assays. Conclusions: Light transmission aggregometry, PFA-100, VerifyNow, and urinary 11-dehydro-thromboxane B2 are all sensitive to the effects of aspirin in healthy individuals. Variables such as aspirin dose, timing between final dose of aspirin and blood collection, and imprecision do not affect the ability of the assays to detect aspirin effect on platelet function.
Idiopathic Nonspecific Interstitial Pneumonia
Hunninghake, Gary W., King, Talmadge E. , Lynch, David A. , Colby, Thomas V. , Galvin, Jeffrey R. , Brown, Kevin M. , Chung, Man Pyo , Cordier, Jean-François, Bois, Roland M. du, Flaherty, Kevin R., Franks, Teri J. , Hansell, David M., Hartman, Thomas E. , Kazerooni, Ella A. , Kim, Dong Soon, Kitaichi, Masanori, Koyama, Takashi , Nagai, Sonoko, Midthun, David E. , Müller, Nestor L., Raghu, Ganesh , Selman, Moisés , Wells, Athol U. , Travis, William D. , Flaherty, Kevin R., Martínez, Fernando J. , Nicholson, Andrew G.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 3, 2008 | Volume: 177 | Issue: 12 | Pages: 1338-1347

10.1164/rccm.200611-1685oc | PMID 18388353 Get It

Abstract Rationale The 2002 American Thoracic Society/European Respiratory Society classification of idiopathic interstitial pneumonias identified nonspecific interstitial pneumonia (NSIP) as a provisional diagnosis. Concern was expressed that NSIP was a “wastebasket” category, difficult to distinguish from other idiopathic interstitial pneumonias. Objectives The following questions were addressed: (1) Is idiopathic NSIP a distinct entity? 2) If so, what are its clinical, radiologic and pathologic characteristics? (3) What is the role of radiology and pathology in establishing the diagnosis? (4) To make a diagnosis of idiopathic NSIP, what other disorders need to be excluded and how should this be done? Methods Investigators who had previously reported cases of idiopathic NSIP were invited to submit cases for review (n = 305). After initial review, cases with complete clinical, radiologic, and pathologic information (n = 193) were reviewed in a series of workshops. Measurements and Main Results Sixty-seven cases were identified as NSIP. Mean age was 52 years, 67% were women, 69% were never-smokers, and 46% were from Asian countries. The most common symptoms were dyspnea (96%) and cough (87%); 69% had restriction. By high-resolution computed tomography, the lower lung zones were predominantly involved in 92% of cases; 46% had a peripheral distribution; 47% were diffuse. Most showed a reticular pattern (87%) with traction bronchiectasis (82%) and volume loss (77%). Lung biopsies showed uniform thickening of alveolar walls with a spectrum of cellular to fibrosing patterns. Five-year survival was 82.3%. Conclusions Idiopathic NSIP is a distinct clinical entity that occurs mostly in middle-aged women who are never-smokers. The prognosis of NSIP is very good.
Response to Letter Regarding Article, “Serial Biomarker Measurements in Ambulatory Patients With Chronic Heart Failure: The Importance of Change Over Time”
Hartman, Karen, Grill, Diane E. , Burritt, Mary F., Rodeheffer, Richard J. , Burnett, John C. , Jaffe, Allan S. , Miller, Wayne L. , Jaffe, Allan S.

Mayo Clinic

Circulation | January 28, 2008 | Volume: 117 | Issue: 4 | Pages: No page available

10.1161/circulationaha.107.740936 Get It

Pharmacology Review
Colby, Christopher E. , Hartman, Tyler, Lang, Tara R.

Mayo Clinic

NeoReviews | November 30, 2007 | Volume: 8 | Issue: 12 | Pages: e547-e550

10.1542/neo.8-12-e547 Get It

Developmental and Genetic Outcomes in Children Conceived Through Assisted Reproductive Technologies
Johnson, Jonathan N. , Hartman, Tyler, Colby, Christopher E.

Mayo Clinic

NeoReviews | October 25, 2007 | Volume: 7 | Issue: 12 | Pages: e615-e626

10.1542/neo.7-12-e615 Get It

Serial Biomarker Measurements in Ambulatory Patients With Chronic Heart Failure
Hartman, Karen, Burritt, Mary F., Grill, Diane E. , Rodeheffer, Richard J. , Burnett, John C. , Jaffe, Allan S. , Miller, Wayne L. , Jaffe, Allan S.

Mayo Clinic

Circulation | June 26, 2007 | Volume: 116 | Issue: 3 | Pages: 249-257

10.1161/circulationaha.107.694562 | PMID 17592074 Get It

Background— Cardiac troponin T (cTnT) and B-type natriuretic peptide (BNP) have been used to estimate prognosis in heart failure; however, most studies have evaluated decompensated patients with single measurements. To determine if there are advantages to serial measurements, we evaluated stable chronic heart failure patients every 3 months for 2 years. Methods and Results— A cohort of 190 New York Heart Association class III–IV heart failure patients was prospectively enrolled from June 2001 to January 2004. Primary end points were death, cardiac transplantation, or hospitalization. At study enrollment cTnT was <0.01 ng/mL in 87 (45.8%) patients, 0.01 to 0.03 ng/mL in 50 (26.3%) patients, and >0.03 ng/mL in 53 (27.9%) patients. An increase in cTnT above normal (<0.01 ng/mL) carried a 3.4-fold increased risk ( P =0.019). Further increases (≥20%) from an elevated level worsened the overall risk (hazard ratio, 5.09; P <0.001). BNP was elevated (>95th percentile for age and gender normal population) in 122 (64.2%) patients. An elevation of BNP from normal at any time during the study was associated with a poor outcome, but, once elevated, further changes in BNP (increases or decreases) remained associated with the same risk (hazard ratio, 5.09; P <0.001). Combined elevations of cTnT (>0.03 ng/mL) and BNP defined the highest risk group (hazard ratio, 8.58; P <0.001). Conclusions— Elevations of cTnT or BNP from normal detected at any time during clinical follow-up in ambulatory patients with chronic heart failure are highly associated with an increased risk of events. Further increases in cTnT contribute to additional risk. Combined elevations of cTnT and BNP contribute the highest risk. The ability to monitor changes by serial measurements adds substantially to the assessment of risk in this patient population.